Sturge-Weber Syndrome

• Aberrant vascular development during embryogenesis: During normal development (weeks 4-8 of gestation), primitive superficial cortical venous plexuses regress and are replaced by deeper cortical veins that drain to superior sagittal sinus. In SWS, this normal regression fails, resulting in persistence of abnormal cortical venous vasculature. These malformed vessels are characterized by thin-walled, abnormally dilated capillaries and venules without normal muscular support. The molecular basis involves dysregulation of vascular patterning genes (particularly GNAQ mutations on chromosome 16q22.2 detected in ~80% of SWS cases), causing abnormal endothelial cell signaling and defective vascular regression. This somatic mutation occurs post-zygotically in neural crest-derived endothelial cells, explaining the sporadic nature and variable distribution of vascular malformations.

• Progressive cerebral hypoxia and ischemia: The abnormal leptomeningeal vasculature creates a pathologic steal phenomenon where blood is diverted through the malformed superficial vessels, reducing perfusion to underlying cortical tissue. Chronic cerebral hypoperfusion is exacerbated by sluggish blood flow through abnormal vessels and inadequate collateral circulation. Over time, repeated episodes of regional hypoxia lead to progressive cortical atrophy, gliosis, and neuronal loss, particularly in the calcarine and central regions. This chronic ischemia explains the progressive cognitive decline and worsening seizure control observed in many SWS patients over decades. Perfusion studies using single-photon emission computed tomography (SPECT) or positron emission tomography (PET) demonstrate hypoperfusion in affected brain regions, correlating with clinical disability.

• Iron deposition and oxidative stress: Chronic low-grade microhemorrhages from abnormal vessel walls and progressive vessel occlusion result in hemosiderin and iron deposition within cortical tissue. Iron catalyzes generation of reactive oxygen species through Fenton chemistry, causing lipid peroxidation, protein oxidation, and DNA damage. This oxidative stress contributes to neuronal dysfunction and accelerates neurodegeneration. Iron deposition also reduces seizure threshold through alteration of inhibitory GABAergic neurotransmission and enhancement of glutamatergic excitability.

• Seizure pathogenesis and epileptogenesis: The combination of cortical irritation from vascular malformation, chronic hypoxia, iron deposition, and gliosis creates a pro-epileptic environment. Seizures arise from the border zone between affected and normal brain rather than from the most severely affected cortex itself, reflecting the critical role of cortical mismatch. Seizures themselves cause additional ischemic injury through increased metabolic demand exceeding cerebral blood flow capacity, creating a vicious cycle of progressive brain injury. Recurrent seizures drive epileptogenesis through activity-dependent mechanisms including loss of GABAergic inhibition and potentiation of glutamatergic signaling.

• Choroidal hemangiomas and glaucoma mechanism: The choroid is supplied by posterior ciliary arteries that share developmental origin with intracranial vessels, explaining why choroidal hemangiomas occur in ~40-50% of SWS cases. These hemangiomas may cause elevated intraocular pressure through pupillary block, angle-closure glaucoma, or direct choroidal expansion. Chronic angle closure can lead to permanent optic nerve damage and vision loss if untreated.

• GNAQ gene mutations (somatic): Approximately 80% of SWS cases harbor somatic gain-of-function mutations in GNAQ (guanine nucleotide-binding protein alpha subunit), particularly the p.R183Q variant. These mutations occur post-zygotically during early neural crest development (before week 8 of gestation), affecting neural crest-derived endothelial cells destined to form cortical vasculature. The GNAQ protein activates phospholipase C signaling, and mutant GNAQ causes constitutive activation of this pathway, leading to abnormal endothelial proliferation and defective vascular regression. The timing of mutation during development determines distribution and severity of vascular involvement—earlier mutations affecting neural crest cells destined for ophthalmic division (V1) distribution explain why V1 port-wine nevi carry highest risk for brain involvement. This is not inherited; it is a de novo somatic mutation explaining the complete absence of family history in SWS.

• Developmental timing during critical vascular patterning window: The critical period for abnormal vascular development occurs during weeks 5-8 of embryogenesis when primitive cortical venous plexuses normally regress. Exposure of developing neural crest to abnormal signaling during this window (whether from GNAQ mutations or potentially other vascular patterning gene defects) prevents normal vascular regression and results in persistence of primitive vasculature. No clear environmental teratogens have been definitively implicated in SWS development.

• No established preventable risk factors: Unlike some neurocutaneous syndromes (e.g., neurofibromatosis with NF1 gene inheritance), SWS is not preventable through genetic counseling or lifestyle modification, as it results from random somatic mutations. Parental age, maternal infections, medications, or nutritional factors have not been convincingly linked to SWS development.

• Port-wine nevus (facial capillary malformation): The hallmark cutaneous finding is present at birth in virtually 100% of SWS cases and is the most important diagnostic clue. The nevus typically follows the distribution of the trigeminal nerve (CN V), most commonly involving the V1 (ophthalmic) and/or V2 (maxillary) distributions, with V3 (mandibular) involvement less common. Early in life, the nevus appears as a flat, pink macule that darkens to deep purple or wine-red with age and becomes increasingly nodular and hypertrophic with vascular ectasia. The nevus darkens and thickens progressively throughout childhood and adulthood; by age 50, approximately 75% of patients develop nodular thickening with surface irregularity. The V1 distribution is particularly significant because the ophthalmic artery arises from the internal carotid system supplying the ipsilateral anterior circulation and cortex, and V1 involvement carries approximately 75% risk of ipsilateral brain involvement versus 25% for V2/V3 distribution alone. The nevus is typically unilateral but can be bilateral in ~15% of cases; bilateral involvement carries higher risk for bilateral brain malformations.

• Seizures (75-80% of patients): Seizures are the most common neurologic manifestation and represent the primary driver of morbidity. Seizures typically begin in infancy or early childhood (median onset age 2 years), occurring initially in ~35% of SWS patients, with additional patients developing seizures over decades of follow-up. The seizures are typically focal motor seizures originating from the cortex adjacent to the angiomatous regions, often with secondary generalization. Seizures may be intractable in 20-30% of patients despite appropriate pharmacotherapy, and early seizure onset (<2 years) and early intractability are associated with worse long-term prognosis including greater cognitive decline. The physiologic basis relates to cortical irritation from vascular malformation, chronic hypoxia, iron deposition, and gliosis creating a low seizure threshold. Seizure severity does not correlate with extent of port-wine nevus, creating a false sense of security in patients with limited cutaneous involvement.

• Stroke-like episodes (25-50% of patients): Acute focal neurologic deficits mimicking stroke occur in 25-50% of patients and are among the most dramatic clinical manifestations. These episodes consist of sudden-onset hemiparesis, hemianopia, aphasia, or other focal deficits lasting hours to days, often followed by complete or near-complete recovery. Stroke-like episodes are typically NOT associated with acute arterial occlusion on angiography (unlike typical stroke) but rather represent acute ischemia from transient worsening of chronic perfusion deficit in the setting of ictal or post-ictal activity. Neuroimaging during stroke-like episodes often shows cortical swelling (edema) and eventually laminar cortical necrosis in the distribution of the angioma. Stroke-like episodes often occur in clusters around seizures or may be triggered by fever, infection, or migraine. The cumulative burden of stroke-like episodes contributes significantly to progressive disability and cognitive decline.

• Progressive cognitive decline and developmental delay: Many SWS patients develop progressive intellectual disability beginning in early childhood, with severity varying from subtle learning difficulties to profound global developmental delay. The cognitive decline reflects progressive cortical atrophy and gliosis from chronic hypoperfusion and recurrent ischemic insults. Approximately 60% of SWS patients have IQ <85, and severe cognitive impairment (IQ <50) occurs in ~20% of patients. Early seizure onset, particularly before age 2 years, is a strong predictor of intellectual disability. Notably, cognitive decline may progress insidiously even in seizure-controlled patients, suggesting that chronic hypoperfusion contributes independent morbidity beyond acute seizures.

• Migraine and headaches: Migraine with aura occurs in 40-60% of SWS patients at rates far exceeding general population prevalence, suggesting shared pathophysiologic mechanisms. Migraine aura may clinically resemble stroke-like episodes, creating diagnostic confusion. The basis for increased migraine prevalence is unclear but may relate to cortical hyperexcitability from ischemia and iron deposition.

• Ocular findings: The ipsilateral eye is affected in ~40-50% of cases, manifesting as choroidal hemangiomas (visible as orange lesions on fundoscopy), iris heterochromia, tortuous episcleral vessels, and diffuse choroidal hemangiomas. Glaucoma develops in 30-70% of patients with ocular involvement, occurring through mechanisms including angle closure from iris heterochromia and pupillary block, elevated episcleral venous pressure, or direct angle infiltration by hemangioma. Glaucoma may be present at birth or develop insidiously, requiring regular ophthalmologic surveillance.

• Physical exam findings: Careful neurologic examination often reveals subtle focal deficits corresponding to angiomatous regions (e.g., facial asymmetry from contralateral hemiparesis in patients with unilateral SWS). Homonymous hemianopia may be detected on confrontation visual fields, reflecting occipital lobe involvement. Hyperreflexia or increased tone on the side contralateral to the angioma may be present. Formal cognitive testing often reveals impairments in executive function, processing speed, and memory.

• Important clinical variants: "Forme fruste" or abortive SWS presentations occur where patients have port-wine nevus without apparent brain or eye involvement on standard imaging; however, subtle perfusion abnormalities are often detectable on advanced neuroimaging. Conversely, rare cases of radiologically evident brain angiomas without visible port-wine nevus have been reported. Bilateral SWS is more aggressive with higher rates of seizures and greater cognitive decline.

• Clinical recognition of port-wine nevus with trigeminal distribution: The presence of a flat, pink to purple capillary malformation in a trigeminal nerve distribution (particularly V1 and/or V2) in an infant or young child should immediately raise suspicion for SWS. The nevus is present at birth in 100% of cases, making it the earliest and most reliable diagnostic clue. However, all port-wine nevi do not represent SWS; approximately 1 in 20,000 to 1 in 50,000 port-wine nevi are associated with SWS. The risk of brain involvement is highest when the nevus involves the V1 distribution (upper eyelid, upper forehead, ipsilateral eye) at approximately 75%, intermediate with V2 distribution (~25%), and lowest with V3 distribution alone (~25%). A critical diagnostic principle is that absence of port-wine nevus does not exclude SWS—rare cases present with brain angiomas without cutaneous findings.

• Neuroimaging: Conventional MRI findings: Brain MRI (preferably with 3-tesla or higher field strength) is the imaging modality of choice for diagnosis and characterization of leptomeningeal angiomatosis. Pathognomonic findings include abnormal cortical venous vasculature, usually most prominent in occipital and posterior parietal distributions, appearing as prominent flow voids and abnormal superficial veins. Cortical calcifications develop over time (often called "tram-track" calcifications when linear) and are best seen on CT but may be evident on susceptibility-weighted imaging (SWI) sequences on MRI. Early in disease, brain MRI may show normal cortical thickness with only vascular abnormality; over time, progressive cortical atrophy develops in the distribution of the angioma. Focal cortical edema or swelling during acute stroke-like episodes is an important finding reflecting acute ischemia. The extent of leptomeningeal involvement on MRI does not always correlate with clinical severity, complicating prognostication. Unilateral brain involvement is most common (~85%), with bilateral involvement in ~15% of cases.

• Advanced neuroimaging: Perfusion studies (SPECT, PET, perfusion-weighted MRI): These modalities provide critical functional information beyond structural findings and are increasingly important for clinical decision-making. Technetium-99m hexamethyl propylene amine oxime (HMPAO) SPECT demonstrates hypoperfusion in the brain region corresponding to the angioma, often extending beyond the anatomic region of visible vascular abnormality. PET with 18F-fluorodeoxyglucose (FDG-PET) shows hypometabolism in affected cortex and is particularly useful for identifying seizure foci. Perfusion-weighted MRI (PWI) and arterial spin labeling (ASL) are non-invasive MRI-based perfusion methods that similarly demonstrate regional hypoperfusion. These perfusion studies are prognostically important: greater extent of hypoperfusion at baseline correlates with higher seizure risk, greater cognitive impairment, and more stroke-like episodes. Some centers use perfusion status to guide treatment intensity.

• Imaging findings: Characteristic cortical calcifications: Over time (typically after age 5-10 years), cortical calcifications develop within the angiomatous cortex, appearing as linear or punctate densities on CT or as susceptibility artifact on SWI-MRI. These calcifications are thought to represent iron deposition, hemosiderin, and mineralization within areas of chronic ischemia and gliosis. The presence and extent of calcifications correlate with disease severity and long-term prognosis—greater calcification burden predicts higher seizure risk and greater cognitive impairment. However, absence of calcifications does not exclude SWS or indicate milder disease.

• Ophthalmologic examination and imaging: Dilated fundoscopic examination should be performed by an ophthalmologist to identify choroidal hemangiomas, iris heterochromia, and episcleral vascular tortuosity. Subtle choroidal hemangiomas may only be apparent on enhanced-depth imaging optical coherence tomography (EDI-OCT) or indocyanine green angiography (ICG-A). Intraocular pressure measurement is essential to screen for glaucoma.

• Diagnostic criteria (modified clinical criteria): SWS diagnosis requires: (1) facial port-wine nevus in trigeminal distribution, PLUS (2) leptomeningeal angiomatosis on neuroimaging (MRI or CT). A confident diagnosis typically includes all three features of port-wine nevus, brain involvement, and ocular findings, but brain involvement is the critical second criterion that distinguishes true SWS from isolated port-wine nevus. Some authors use the term "Sturge-Weber

Acute stabilisation

• Status epilepticus: a benzodiazepine (lorazepam IV, or intramuscular midazolam if no access) is first-line, followed by a second-line agent — fosphenytoin, levetiracetam, or valproate — per the American Epilepsy Society status epilepticus guideline. Seizures worsen the underlying perfusion deficit, so prolonged ictal activity is itself an ischemic insult.
• Acutely elevated intraocular pressure: emergent ophthalmology involvement, topical aqueous suppressants and systemic acetazolamide, consistent with the American Academy of Ophthalmology childhood glaucoma Preferred Practice Pattern.

First-line maintenance

• Anti-seizure medication for focal epilepsy: sodium-channel blockers (oxcarbazepine or carbamazepine) or levetiracetam are standard first choices; expert consensus recommendations developed through the Sturge-Weber Foundation multidisciplinary panels favour early, aggressive seizure control because early-onset and refractory seizures predict cognitive decline.
• Low-dose aspirin: widely used in specialist centres to reduce stroke-like episodes and thrombosis within sluggish malformed venous channels; supported by consensus opinion rather than randomized data.
• Supportive measures: avoid dehydration, hyperthermia, and hypoxia, which precipitate stroke-like episodes; developmental surveillance and early intervention referral as endorsed by the AAP.

Escalation and definitive therapy

• Medically refractory epilepsy: presurgical evaluation (video-EEG, MRI, FDG-PET) per AAN/AES practice standards. Options include focal resection, lobectomy, or hemispherectomy/hemispherotomy for unilateral disease — the most effective intervention, with the best cognitive outcomes when performed early. Vagus nerve stimulation and corpus callosotomy are palliative.
• Port-wine nevus: pulsed-dye laser (595 nm), begun in infancy before vessel ectasia and nodularity develop.
• Glaucoma: prostaglandin analogues and beta blockers (timolol) medically; goniotomy/trabeculotomy for infantile onset, filtering surgery or drainage device later.

Cautions

• Vigabatrin is problematic given baseline visual-field risk; carbamazepine requires *HLA-B\*1502* screening in at-risk Asian ancestry.
• Aspirin is withheld during varicella or influenza (Reye syndrome).
• There is no role for anticoagulation or thrombolysis in stroke-like episodes, which are not arterial occlusions.

Neurologic (highest morbidity)

• Refractory epilepsy and status epilepticus: cortical irritation, iron deposition, and gliosis at the border zone lower seizure threshold. Status epilepticus is a neurologic emergency — each event increases metabolic demand beyond an already impaired perfusion reserve, extending the ischemic lesion. Signalled by clustering focal motor seizures with prolonged post-ictal deficit.
• Stroke-like episodes and fixed hemiparesis/hemianopia: venous stasis and steal produce acute hypoperfusion; the signal is abrupt focal deficit with cortical swelling on MRI and no arterial occlusion on angiography. Recurrent episodes leave permanent deficit and laminar cortical necrosis.
• Progressive cognitive decline and behavioural disorder: cumulative cortical atrophy; may progress even when seizures are controlled.

Ophthalmologic

• Glaucoma with optic atrophy: elevated episcleral venous pressure or angle anomaly. Infantile presentation shows buphthalmos, corneal clouding, tearing, photophobia — acute angle closure with a hard, red eye is an emergency. Requires lifelong IOP surveillance since onset can be bimodal (infancy and later childhood/adulthood).
• Exudative retinal detachment from a diffuse choroidal hemangioma; amblyopia from any of the above.

Other disease complications

• Soft-tissue and bony hypertrophy of the affected face with gingival overgrowth; endocrinopathy — growth hormone deficiency and central hypothyroidism are reported at higher-than-expected rates and should prompt growth monitoring.

Treatment-related

• Hemispherectomy: expected contralateral hemiparesis and homonymous hemianopia, plus hydrocephalus and late superficial hemosiderosis.
• Anti-seizure drugs: hyponatremia (oxcarbazepine), Stevens–Johnson syndrome with carbamazepine (HLA-B\*1502), behavioural aggression (levetiracetam), visual-field constriction (vigabatrin), nephrolithiasis and oligohidrosis (topiramate/zonisamide).
• Aspirin: bleeding and Reye syndrome risk during varicella/influenza.
• Pulsed-dye laser: blistering, dyspigmentation, scarring; recurrence of nevus darkening over time.

• The buzzword set: port-wine stain in a V1 trigeminal distribution + leptomeningeal angiomatosis + tram-track (gyriform) cortical calcifications on CT. Calcifications take years to appear — their absence in an infant never excludes the diagnosis.
• Single best next step for a newborn with a V1 port-wine nevus: contrast-enhanced brain MRI plus ophthalmologic exam with intraocular pressure measurement. A negative MRI in the first months of life can be falsely reassuring and is often repeated after age one.
• The association examiners test: V1 (ophthalmic division) involvement — especially forehead/upper eyelid — is what predicts intracranial and ocular disease. V2/V3-only nevi carry much lower risk.
• Genetics: somatic mosaic GNAQ p.R183Q mutation, post-zygotic. Sporadic, not inherited — no recurrence risk counselling, no family history, no autosomal dominant pattern. This distinguishes it from NF1, tuberous sclerosis, and von Hippel–Lindau.
• Stroke-like episodes are venous/perfusional, not embolic: MRI shows cortical swelling without arterial occlusion. Thrombolysis and anticoagulation are wrong answers; low-dose aspirin and seizure control are the consensus approach.
• Glaucoma is lifelong: it may present at birth with buphthalmos or emerge in adolescence/adulthood, so "no glaucoma at birth" does not end surveillance.
• Refractory unilateral epilepsy → the definitive answer is epilepsy surgery, up to hemispherectomy, done early to exploit neuroplasticity.
• Common distractors: nevus simplex ("stork bite/angel kiss") is a midline macule that fades — not a port-wine stain; Klippel–Trénaunay (PIK3CA) gives limb capillary malformation with overgrowth, not leptomeningeal disease; tuberous sclerosis gives ash-leaf macules and cortical tubers; von Hippel–Lindau gives retinal hemangioblastomas, not choroidal hemangioma.